MEDIF - MediPharm Labs Corp.

Other OTC - Other OTC Delayed Price. Currency in USD
4.0571
+0.2061 (+5.35%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close3.8510
Open3.7600
BidN/A x N/A
AskN/A x N/A
Day's Range3.7600 - 4.0571
52 Week Range0.9125 - 5.6500
Volume140,610
Avg. Volume369,005
Market Cap468.116M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • CNW Group2 days ago

    Live Investor Conference & Webinar June 20th

    Live Investor Conference & Webinar June 20th

  • Cronos Stock Is Interesting… but Patience Is Required
    InvestorPlace13 days ago

    Cronos Stock Is Interesting… but Patience Is Required

    Cronos Group (NASDAQ:CRON) has certainly lost its buzz. The company was the hottest name in marijuana just six months ago. After announcing its huge deal with Altria (NYSE:MO), the sky was the limit. CRON stock launched from $10 at the start of the year to as high as $25.Source: Shutterstock But the euphoria has waned. Shares skidded back to $15 earlier this year and have traded sideways for the past two months.It seems that a lot of folks are giving up on CRON stock. With more dealmaking and exciting happenings going on in other pot stocks, it would appear that people are selling out of their Cronos in order to put money elsewhere. But is that the right reaction? I'd argue that while Cronos has had a bit of a quiet period lately, it's still one of the stronger picks for longer-term investors in the space.InvestorPlace - Stock Market News, Stock Advice & Trading Tips What's the Story, Cronos?InvestorPlace contributor Vince Martin summarized CRON stock's problem well in his recent article. Martin explained that Cronos Group stock "lacks a compelling narrative." He shows that, in a complex and fast-changing market like marijuana, companies need to specialize -- have some claim to fame -- in order to maintain investor interest. He wrote: "A stock needs a succinct bull case, an elevator pitch so to speak. And most of the well-covered cannabis plays have that type of case." * 7 Bank Stocks to Leave in the Vault I agree fully with the premise. CRON stock is clearly losing some of its luster as investors shift to other marijuana plays that have more going on right now. As Martin notes, Cronos isn't particularly strong in any one segment of the market. Its production capacity isn't even in the top 10 in Canada. Its overseas brands aren't that strong. The company has all that Altria money, but it's not clear how it's going to put it to work yet. There is some guidance toward its long-term plans, but there's not a lot of specifics in the near-term for investors to get excited about. MediPharm Deal Signals a Change in DirectionEarlier in May, Cronos group announced a major partnership with MediPharm (OTCMKTS:MEDIF). Cronos will buy C$30 million in marijuana from MediPharm and pay the company an additional sum of money to handle some of the product processing as well.While this is clearly great news for MediPharm, the takeaway for Cronos is more nuanced. On the one hand, Cronos clearly isn't rushing the buildout of its own capacity; in theory, Cronos could have handled this production capacity on its own by constructing the Peace Naturals building Unit No. 4 faster.Instead, it seems that post-Altria deal, Cronos is more focused on its longer-term goals rather than boosting production rapidly today. Perhaps, like Tilray (NASDAQ:TLRY), Cronos has realized that simple marijuana production is never going to be an especially profitable venture. It's important to note that Altria makes its money off its brands and intellectual property rather than actually growing tobacco. Over time, profits in the marijuana industry will similarly shift from the farmers to the brand and technology owners.It's hard to say what exactly Cronos is aiming for, since it hasn't laid out a clear road map for investors. But it's not hard to imagine a future where Cronos leads the world in marijuana vaping. Vaping is clearly a top priority for Altria given its actions with Juul. Cronos stock will be worth multiples of what it is today if Altria is able to make Cronos the Juul of the marijuana space. CRON Stock VerdictCRON stock offers a classic test of investors' patience. For long-term investors, there are plenty of good reasons to like CRON stock as opposed to its marijuana rivals. For one thing, the company has a ton of cash and a strong backer. It doesn't need to move quickly. Taking time to deploy its capital in small doses, such as we see with the MediPharm Labs deal, gives it the opportunity to have a lot of shots on goal while the industry evolves. * 7 Stocks to Buy That Are Near 52-Week Highs But for people wanting a story that will play out in 2019, CRON stock doesn't have a lot of offer. As Martin so correctly states, most of the leading pot stocks have a clear, easy-to-understand narrative, or thesis, driving their strategy. Cronos, by contrast, is doing some of this and some of that, knowing that its alliance with Altria gives it plenty of time to execute on its plans.That may lead to CRON stock struggling in the short-term. But for longer-term holders, Cronos' more deliberate strategy may pay off, as other competitors that move too fast, fail to adapt to the rapidly changing marijuana market conditions.At the time of this writing, Ian Bezek owned MO stock. You can reach him on Twitter at @irbezek. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 10 Heavily Shorted Stocks to Sell -- Because the Bears Are Right * 7 Bank Stocks to Leave in the Vault * 7 Stocks for You to Profit From (Legal) Insider Trading Compare Brokers The post Cronos Stock Is Interestinga€¦ but Patience Is Required appeared first on InvestorPlace.

  • GlobeNewswire18 days ago

    MediPharm Labs Corp. Announces Upsize of Bought Deal Financing to $75 Million

    MediPharm Labs Corp. (LABS.V) (MEDIF) (MLZ.F) (“MediPharm Labs” or the “Company”), a leader in specialized, research-driven cannabis extraction and cannabinoid isolation, is pleased to announce that, due to strong demand, it has entered into a revised agreement with syndicate of underwriters led by Scotiabank, GMP Securities L.P. and BMO Capital Markets (collectively the “Underwriters”), to increase the size of its previously announced $60,023,250 “bought deal” offering. Pursuant to the upsized deal terms, the Underwriters have agreed to purchase, on a “bought deal” basis, an additional 2,699,000 common shares of the Company (“Common Shares”) at the same issue price of $5.55 per Common Share (the “Offering Price”) for aggregate gross proceeds of $75,002,700 (the “Offering”).

  • Benzinga19 days ago

    MediPharm Labs Gets C$60M By Selling Stock

    MediPharm Labs Corp. (TSXV: LABS) (OTC: MEDIF ), a company that specializes in research-driven cannabis extraction and cannabinoid isolation, on Tuesday announced an agreement with Bank of Nova Scotia ...

  • Why Medicon Hellas S.A.’s (ATH:MEDIC) Return On Capital Employed Might Be A Concern
    Simply Wall St.20 days ago

    Why Medicon Hellas S.A.’s (ATH:MEDIC) Return On Capital Employed Might Be A Concern

    Today we'll evaluate Medicon Hellas S.A. (ATH:MEDIC) to determine whether it could have potential as an investment...

  • GlobeNewswire24 days ago

    UPDATE - New York City Icahn School of Medicine at Mount Sinai and Renowned Global Researcher Dr. Hurd, Select MediPharm Labs to Support 500 Patient Major Clinical Study And “CBD International Consortium” to Develop Treatment of Opioid Addiction

    MediPharm Labs Corp. (LABS.V) (MEDIF) (MLZ.F) (“MediPharm Labs”) a leader in specialized, research-driven cannabis extraction and cannabinoid isolation, is pleased to announce it has been selected by the Icahn School of Medicine at Mount Sinai Hospital, New York City (“Icahn School of Medicine”), to participate in a clinical trial dedicated to developing a non-addictive oral gelcap medication for the treatment of opioid use disorder through anti-anxiety intervention utilizing hemp-derived CBD combined with a proprietary formula (the “Formula”). This will be a U.S. and international large-scale, multi-site clinical trial that will include at least 500 patients spanning the United States, Canada, Australia, Europe and Jamaica.

  • GlobeNewswire25 days ago

    New York City Ichan School of Medicine at Mount Sinai and Renowned Global Researcher Dr. Hurd, Select MediPharm Labs to Support 500 Patient Major Clinical Study and “CBD International Consortium” to Develop Treatment of Opioid Addiction

    MediPharm Labs Corp. (LABS.V) (MEDIF) (MLZ.F) (“MediPharm Labs”) a leader in specialized, research-driven cannabis extraction and cannabinoid isolation, is pleased to announce it has been selected by The Mount Sinai Hospital, New York City (“Mount Sinai”), to participate in a clinical trial dedicated to developing a non-addictive oral gelcap medication for the treatment of opioid use disorder through anti-anxiety intervention utilizing hemp-derived CBD combined with a proprietary formula (the “Formula”). This will be a U.S. and international large-scale, multi-site clinical trial that will include at least 500 patients spanning the United States, Canada, Australia, Europe and Jamaica.

  • GlobeNewswire26 days ago

    MediPharm Labs Australia Awarded Cannabis Manufacturing Licence From Office of Drug Control – Establishes Asia-Pacific Foothold

    MediPharm Labs Corp. (LABS.V) (MEDIF) (MLZ.F) (“MediPharm Labs” or the “Company”) a leader in specialized, research-driven cannabis extraction and cannabinoid isolation, is pleased to announce that its subsidiary, MediPharm Labs Australia Pty. Ltd. (“MediPharm Labs Australia”), has received its cannabis manufacturing licence (the “Licence”) from the Australian Office of Drug Control under the Narcotics Drugs Act 1967  on May 21, 2019. This is a significant milestone for MediPharm Labs that establishes the Company as an early mover in the Australian cannabis industry. In addition, MediPharm Labs Australia is expected to provide the Company with a global supply chain platform and a foothold in the Asia-Pacific region.

  • GlobeNewswire26 days ago

    MediPharm Labs Announces Addition to $1.2B MJ ETFMG Alternative Harvest ETF (USA)

    TORONTO, May 21, 2019 -- MediPharm Labs Corp. (TSXV: LABS) (OTCQX: MEDIF) (FSE:MLZ) (“MediPharm Labs”) a leader in specialized, research-driven cannabis extraction and.

  • GlobeNewswirelast month

    Emerald Health Therapeutics Introduces Unique Premium CBD Oil SYNC 25 to British Columbia Recreational Marketplace

    VANCOUVER, British Columbia, May 17, 2019 -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has shipped 6,000 40 ml units of its SYNC 25 CBD oil to the.

  • GlobeNewswirelast month

    MediPharm Labs Signs Committed Term Sheet for $20 Million Debt Facility With Schedule 1 Bank

    MediPharm Labs Corp. (LABS.V) (MEDIF) (MLZ.F) (“MediPharm Labs”) a leader in specialized, research-driven cannabis extraction and cannabinoid isolation, is pleased to announce that its wholly-owned subsidiary, MediPharm Labs Inc. (“MediPharm”), has signed a committed term sheet for a $20 million senior secured revolving credit facility ("Credit Facility") from a Canadian Schedule 1 Bank.  The Credit Facility is intended to provide MediPharm Labs access to non-dilutive capital to fund planned growth, as well as for general corporate and working capital purposes. The Credit Facility consists of a $15 million operating loan with a one-year term and a $5 million non-revolving equipment term loan with a three-year term. The Credit Facility, once closed, will bear interest at the Schedule 1 Bank’s prime lending rate plus 1.85% per annum.

  • MarketWatchlast month

    Cronos, MediPharm enter supply deal for private-label cannabis concentrate

    Cronos Group Inc. announced Tuesday a supply deal with MediPharm Labs Corp. , in which MediPharm will supply Cronos with about C$30 million ($22.3 million) of private label cannabis concentrate over 18 months. With certain renewal and purchase options, the deal could potential reach C$60 million over 24 months. The U.S.-listed shares of Cronos rose 3.1% premarket, while MediPharm's stock was still inactive. The companies have also entered into a multi-year tolling agreement, in which Cronos will supply bulk cannabis to MediPharm's extraction facility, to fulfill certain processing needs. "As the industry develops and matures, we see opportunity to work with companies like MediPharm Labs that provide specialized, high-quality services and inputs for our products," said Cronos Chief Executive Mike Gorenstein. Cronos's stock has rallied 37.2% year to date through Monday and MediPharm shares have rocketed nearly 4-fold (280%), while the ETFMG Alternative Harvest ETF has climbed 30.4% and the S&P 500 has gained 12.2%.

  • GlobeNewswirelast month

    Cronos Group and MediPharm Labs Enter $30 Million Multi-Year Private Label Cannabis Concentrate Supply Agreement with Potential to Increase to $60 Million

    MediPharm Labs Corp. (LABS.V) (MEDIF) (“MediPharm Labs”) a leader in specialized, research-driven cannabis extraction and cannabinoid isolation, is pleased to announce that it has entered into a multi-year supply agreement with Cronos Group Inc. (CRON) (CRON) (“Cronos Group”). MediPharm Labs will supply Cronos Group with approximately $30 million of high-quality private label cannabis concentrate over 18-months, and, subject to certain renewal and purchase options, potentially up to $60 million over 24-months.  In addition, Cronos Group has selected MediPharm Labs’ state of the art extraction facility in Barrie, Ontario, as a preferred partner to fulfill certain of its processing needs, under a separate tolling arrangement.

  • GlobeNewswirelast month

    Cronos Group and MediPharm Labs Enter Cannabis Concentrate Supply Agreement

    Cronos Group Inc. (CRON.TO) (CRON.TO) (“Cronos Group” or the “Company”), is pleased to announce that it has entered into a multi-year supply agreement with MediPharm Labs Corp. (LABS.V) (MEDIF) (“MediPharm Labs”). MediPharm Labs will supply Cronos Group with approximately $30 million of high-quality private label cannabis concentrate over 18-months, and, subject to certain renewal and purchase options, potentially up to $60 million over 24-months.

  • Benzingalast month

    MediPharm Labs Revenue Rises 115% Quarter-Over-Quarter

    MediPharm Labs Corp. (OTC: MEDIF ) announced first-quarter financial results Friday. The global extraction, distillation, purification and cannabinoid isolation company generated revenue of $22 million, ...

  • GlobeNewswirelast month

    MediPharm Labs Announces Q1 2019 Revenue of $22 Million and Adjusted EBITDA of $4.3 Million

    TORONTO, May 10, 2019 -- MediPharm Labs Corp. (TSXV: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven.

  • GlobeNewswirelast month

    MediPharm Labs Sets Date to Release First Quarter 2019 Financial Results

    TORONTO, May 08, 2019 -- MediPharm Labs Corp. (TSXV: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven.

  • GlobeNewswirelast month

    MediPharm Labs Announces Upgrade to the OTCQX Best Market in the U.S. Under Symbol “MEDIF”

    TORONTO, May 02, 2019 -- MediPharm Labs Corp. (TSXV: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven.

  • OTC Markets Group Welcomes MediPharm Labs Corp. to OTCQX
    PR Newswirelast month

    OTC Markets Group Welcomes MediPharm Labs Corp. to OTCQX

    NEW YORK , May 2, 2019 /PRNewswire/ --   OTC Markets Group Inc.  (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced MediPharm Labs Corp.  (TSX-V: LABS ; ...

  • GlobeNewswire2 months ago

    MediPharm Labs Appoints Renowned Medical Expert and Pharmaceutical Researcher Dr. Paul Tam to its Board of Directors

    MediPharm Labs Corp. (LABS.V) (MEDIF) (MLZ.F) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven cannabis extraction, distillation, purification and cannabinoid isolation, is pleased to announce the appointment of Dr. Paul Tam, MBBS, FRCP(C), FACP to its Board of Directors effective immediately, subject to the necessary regulatory approvals. In connection with the Company’s goal of satisfying non-venture requirements for corporate governance and financial oversight, Dr. Tam will also replace Chris Hobbs on the Company’s Audit Committee resulting in an Audit Committee fully comprised of independent directors in accordance with National Instrument 52-110 – Audit Committees. “Dr. Paul Tam is a tremendous addition to our board and will be a valuable independent director and contributor as we continue to deepen our medical expertise through this next phase of growth,” said Patrick McCutcheon, Chief Executive Officer, MediPharm Labs.

  • GlobeNewswire2 months ago

    MediPharm Labs Appoints Former Johnson & Johnson Group Product Director as Chief Strategy Officer

    TORONTO, April 29, 2019 -- MediPharm Labs Corp. (TSXV: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven.

  • Newsfile2 months ago

    MediPharm Labs Executing on International Cannabis Extracts Strategy -- CFN Media

    Seattle, Washington--(Newsfile Corp. - April 25, 2019) - CFN Media Group ("CFN Media"), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing MediPharm Labs and its plans for global expansion.Canadian companies have a bit of a head start on those from other countries where the legal cannabis framework is not as comprehensive or advanced. In many ways, countries around the globe look ...

  • GlobeNewswire2 months ago

    MediPharm Labs Announces DTC Eligibility, Increasing Accessibility for US Investors

    MediPharm Labs Corp. (LABS.V) (MEDIF) (MLZ.F) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven cannabis extraction, distillation, purification and cannabinoid isolation, is pleased to announce it has received Depository Trust Company (DTC) eligibility for its common shares in the United States. “DTC eligibility” simplifies the process of trading and transferring the Company’s common shares between brokerages in the U.S. “We are pleased that MediPharm Labs common shares are now considered to be “DTC Eligible”, to facilitate the trading of our common shares in the U.S. markets”, said Patrick McCutcheon, Chief Executive Officer, MediPharm Labs.

  • GlobeNewswire2 months ago

    MediPharm Labs Announces OTC Ticker Symbol Change to “MEDIF”

    TORONTO, April 09, 2019 -- MediPharm Labs Corp. (TSXV: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven.